TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Multicenter, Double-Blind, Placebo Controlled, Non-Inferiority Study Assessing the Effects of Ciclesonide Metered Dose Inhaler 50 Mg/Day and 200 Mg/Day (Ex-Valve) Administered Once Daily on Growth in Children With Mild Persistent Asthma
Brief Summary: The primary objective is to determine if CIC 50 mg/day or 200 mg/day (ex-valve) administered once daily in the morning is non-inferior to placebo with respect to growth velocity in children with mild persistent asthma following a 12-month treatment period

The secondary objective is to investigate changes in growth in terms of bone age (wrist X-ray), and maintenance of asthma control and safety with ciclesonide


Options:
A: Intervention Type: DRUG; Name: Ciclesonide; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ciclesonide | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone | Intervention Type: DRUG; Name: Ciclesonide; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Fluticasone; Assigned to Arm(s): 2
C: Intervention Type: DRUG; Name: ciclesonide; Assigned to Arm(s): N/A
D: Arm Label: Ciclesonide 40 µg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ciclesonide, Drug: Placebo, Drug: Salbutamol | Arm Label: Ciclesonide 80 µg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ciclesonide, Drug: Placebo, Drug: Salbutamol | Arm Label: Ciclesonide 160 µg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ciclesonide, Drug: Placebo, Drug: Salbutamol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Salbutamol | Intervention Type: DRUG; Name: Ciclesonide; Assigned to Arm(s): Ciclesonide 160 µg, Ciclesonide 40 µg, Ciclesonide 80 µg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Ciclesonide 160 µg, Ciclesonide 40 µg, Ciclesonide 80 µg, Placebo | Intervention Type: DRUG; Name: Salbutamol; Assigned to Arm(s): Ciclesonide 160 µg, Ciclesonide 40 µg, Ciclesonide 80 µg, Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Multicenter, Double-Blind, Placebo Controlled, Non-Inferiority Study Assessing the Effects of Ciclesonide Metered Dose Inhaler 50 Mg/Day and 200 Mg/Day (Ex-Valve) Administered Once Daily on Growth in Children With Mild Persistent Asthma
Brief Summary: The primary objective is to determine if CIC 50 mg/day or 200 mg/day (ex-valve) administered once daily in the morning is non-inferior to placebo with respect to growth velocity in children with mild persistent asthma following a 12-month treatment period

The secondary objective is to investigate changes in growth in terms of bone age (wrist X-ray), and maintenance of asthma control and safety with ciclesonide


Options:
A: Intervention Type: DRUG; Name: ciclesonide; Assigned to Arm(s): N/A
B: Arm Label: Salmeterol/ fluticasone propionate Diskus® inhaler 50/100 mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Salmeterol/ fluticasone propionate Diskus® inhaler 50/100 mcg | Arm Label: fluticasone propionate 2 x 100 mcg; Type: OTHER; Interventions: Drug: fluticasone propionate 2 x 100 mcg | Intervention Type: DRUG; Name: Salmeterol/ fluticasone propionate Diskus® inhaler 50/100 mcg; Assigned to Arm(s): Salmeterol/ fluticasone propionate Diskus® inhaler 50/100 mcg | Intervention Type: DRUG; Name: fluticasone propionate 2 x 100 mcg; Assigned to Arm(s): fluticasone propionate 2 x 100 mcg
C: Intervention Type: DRUG; Name: inhaled corticosteroids; Assigned to Arm(s): N/A
D: Intervention Type: BEHAVIORAL; Name: Home-based adherence monitoring; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Multicenter, Double-Blind, Placebo Controlled, Non-Inferiority Study Assessing the Effects of Ciclesonide Metered Dose Inhaler 50 Mg/Day and 200 Mg/Day (Ex-Valve) Administered Once Daily on Growth in Children With Mild Persistent Asthma
Brief Summary: The primary objective is to determine if CIC 50 mg/day or 200 mg/day (ex-valve) administered once daily in the morning is non-inferior to placebo with respect to growth velocity in children with mild persistent asthma following a 12-month treatment period

The secondary objective is to investigate changes in growth in terms of bone age (wrist X-ray), and maintenance of asthma control and safety with ciclesonide


Options:
A: Arm Label: Daily ICS + Rescue ICS; Type: EXPERIMENTAL; Interventions: Drug: Beclomethasone dipropionate, Drug: Albuterol sulfate | Arm Label: Daily ICS; Type: ACTIVE_COMPARATOR; Interventions: Drug: Beclomethasone dipropionate, Drug: Albuterol sulfate | Arm Label: Rescue ICS; Type: EXPERIMENTAL; Interventions: Drug: Beclomethasone dipropionate, Drug: Albuterol sulfate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Albuterol sulfate | Intervention Type: DRUG; Name: Beclomethasone dipropionate; Assigned to Arm(s): Daily ICS, Daily ICS + Rescue ICS | Intervention Type: DRUG; Name: Beclomethasone dipropionate; Assigned to Arm(s): Daily ICS + Rescue ICS, Rescue ICS | Intervention Type: DRUG; Name: Albuterol sulfate; Assigned to Arm(s): Daily ICS, Daily ICS + Rescue ICS, Placebo, Rescue ICS
B: Intervention Type: DRUG; Name: ciclesonide; Assigned to Arm(s): N/A
C: Arm Label: 1 Budesonide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Budesonide | Arm Label: 2 Nedocromil; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nedocromil | Arm Label: 3 Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3 Placebo | Intervention Type: DRUG; Name: Nedocromil; Assigned to Arm(s): 2 Nedocromil | Intervention Type: DRUG; Name: Budesonide; Assigned to Arm(s): 1 Budesonide
D: Intervention Type: DRUG; Name: inhaled corticosteroids; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The purpose of this study is to further determine whether benazepril, could safely slow the progression of renal dysfunction in non-diabetic patients with advanced renal insufficiency.


Options:
A: Intervention Type: DRUG; Name: Telmisartan; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Combination of Telmisartan and Ramipril; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Ramipril; Assigned to Arm(s): N/A
B: Arm Label: A,AIIA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Candesartan and enalapril | Arm Label: A, ACE-I; Type: ACTIVE_COMPARATOR; Interventions: Drug: candesartan and enalapril | Arm Label: C, AIIA; Type: ACTIVE_COMPARATOR; Interventions: Drug: candesartan and enalapril | Arm Label: C, ACE; Type: ACTIVE_COMPARATOR; Interventions: Drug: candesartan and enalapril | Intervention Type: DRUG; Name: Candesartan and enalapril; Assigned to Arm(s): A,AIIA | Intervention Type: DRUG; Name: candesartan and enalapril; Assigned to Arm(s): A, ACE-I | Intervention Type: DRUG; Name: candesartan and enalapril; Assigned to Arm(s): C, AIIA | Intervention Type: DRUG; Name: candesartan and enalapril; Assigned to Arm(s): C, ACE
C: Arm Label: Telmisartan; Type: ACTIVE_COMPARATOR; Interventions: Drug: Telmisartan | Arm Label: Enalapril; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Telmisartan; Assigned to Arm(s): Telmisartan
D: Intervention Type: DRUG; Name: Benazepril; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Intermittent Preventive Treatment of Malaria With Sulfadoxine-Pyrimethamine in HIV-Seropositive and HIV-Seronegative Pregnant Women in Zambia
Brief Summary: Prevention of malaria in pregnancy is critical given the high incidence of malaria in Zambia and its serious impact on both maternal and infant survival. Intermittent presumptive treatment with sulfadoxine-pyrimethamine has been shown to be highly efficacious for reducing the risk of malaria in pregnancy. However, based on a study done in western Kenya, HIV-infected pregnant women may need more frequent dosing of SP, i.e., on a monthly basis rather than the standard 2-dose regimen given during the second and third trimesters, as HIV appears to reduce the effectiveness of the SP drug combination. The goal of this study was to evaluate the efficacy of the standard dosing regimen in comparison to an intensive monthly SP dosing schedule in HIV-positive women.


Options:
A: Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Drug: Sulfadoxine-pyrimethamine treatment twice during pregnancy | Arm Label: Monthly SP; Type: EXPERIMENTAL; Interventions: Drug: Sulfadoxine-pyrimethamine at 4-week intervals | Arm Label: AZI-SP; Type: EXPERIMENTAL; Interventions: Drug: Sulfadoxine-pyrimethamine every 4 weeks + azithromycin twice | Intervention Type: DRUG; Name: Sulfadoxine-pyrimethamine treatment twice during pregnancy; Assigned to Arm(s): Control | Intervention Type: DRUG; Name: Sulfadoxine-pyrimethamine at 4-week intervals; Assigned to Arm(s): Monthly SP | Intervention Type: DRUG; Name: Sulfadoxine-pyrimethamine every 4 weeks + azithromycin twice; Assigned to Arm(s): AZI-SP
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Cotrimoxazole | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sulfadoxine-pyrimethamine | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Cotrimoxazole | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sulfadoxine-pyrimethamine | Intervention Type: DRUG; Name: Cotrimoxazole; Assigned to Arm(s): 1, 3 | Intervention Type: DRUG; Name: Sulfadoxine-pyrimethamine; Assigned to Arm(s): 2, 4
C: Arm Label: IPTp-DP; Type: EXPERIMENTAL; Interventions: Drug: IPTp-DP | Arm Label: ISTp-DP; Type: EXPERIMENTAL; Interventions: Drug: ISTp-DP | Arm Label: IPTp-SP; Type: ACTIVE_COMPARATOR; Interventions: Drug: IPTp-SP | Intervention Type: DRUG; Name: IPTp-SP; Assigned to Arm(s): IPTp-SP | Intervention Type: DRUG; Name: IPTp-DP; Assigned to Arm(s): IPTp-DP | Intervention Type: DRUG; Name: ISTp-DP; Assigned to Arm(s): ISTp-DP
D: Intervention Type: DRUG; Name: Sulfadoxine-pyrimethamine (Fansidar); Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Intermittent Preventive Treatment of Malaria With Sulfadoxine-Pyrimethamine in HIV-Seropositive and HIV-Seronegative Pregnant Women in Zambia
Brief Summary: Prevention of malaria in pregnancy is critical given the high incidence of malaria in Zambia and its serious impact on both maternal and infant survival. Intermittent presumptive treatment with sulfadoxine-pyrimethamine has been shown to be highly efficacious for reducing the risk of malaria in pregnancy. However, based on a study done in western Kenya, HIV-infected pregnant women may need more frequent dosing of SP, i.e., on a monthly basis rather than the standard 2-dose regimen given during the second and third trimesters, as HIV appears to reduce the effectiveness of the SP drug combination. The goal of this study was to evaluate the efficacy of the standard dosing regimen in comparison to an intensive monthly SP dosing schedule in HIV-positive women.


Options:
A: Intervention Type: DRUG; Name: Sulfadoxine-pyrimethamine (Fansidar); Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Monthly sulfadoxine/pyrimethamine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: 2-dose sulfadoxine/pyrimethamine; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: ARTEMETHER + LUMEFANTRINE VS. SULFADOXINE + PYRIMETHAMINE; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Amodiaquine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Sulphadoxine-pyrimethamine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Chloroquine; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Intermittent Preventive Treatment of Malaria With Sulfadoxine-Pyrimethamine in HIV-Seropositive and HIV-Seronegative Pregnant Women in Zambia
Brief Summary: Prevention of malaria in pregnancy is critical given the high incidence of malaria in Zambia and its serious impact on both maternal and infant survival. Intermittent presumptive treatment with sulfadoxine-pyrimethamine has been shown to be highly efficacious for reducing the risk of malaria in pregnancy. However, based on a study done in western Kenya, HIV-infected pregnant women may need more frequent dosing of SP, i.e., on a monthly basis rather than the standard 2-dose regimen given during the second and third trimesters, as HIV appears to reduce the effectiveness of the SP drug combination. The goal of this study was to evaluate the efficacy of the standard dosing regimen in comparison to an intensive monthly SP dosing schedule in HIV-positive women.


Options:
A: Intervention Type: DRUG; Name: Sulfadoxine-Pyrimethamine (Fansidar); Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: ITNs; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Sulphadoxine-pyrimethamine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Sulphadoxine-pyrimethamine, amodiaquine; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Sulfadoxine-pyrimethamine (Fansidar); Assigned to Arm(s): N/A
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intermittent preventive treatment:sulphadoxine-pyrimethamine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: Insecticide-treated mosquito bed net | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intermittent preventive treatment:sulphadoxine-pyrimethamine, Device: Insecticide-treated mosquito bed net | Intervention Type: DRUG; Name: Intermittent preventive treatment:sulphadoxine-pyrimethamine; Assigned to Arm(s): 1, 3 | Intervention Type: DEVICE; Name: Insecticide-treated mosquito bed net; Assigned to Arm(s): 2, 3

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Physicians' Health Study II: Trial of Vitamins in the Chemoprevention of Cancer, CVD, and Eye Disease
Brief Summary: The use of vitamin E, vitamin C, beta carotene, and/or multivitamins may keep cancer, cardiovascular disease, eye diseases, or cognitive decline from occurring. This randomized clinical trial studied vitamin E, vitamin C, beta carotene, and/or multivitamins to see how well they work compared with placebos in preventing cancer, cardiovascular disease, eye disease, and cognitive decline in male doctors aged 50 years and older.


Options:
A: Arm Label: Vitamin E; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin E | Arm Label: Vitamin C; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin C | Arm Label: Multivitamin; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Multivitamin | Arm Label: Beta-carotene; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Beta-carotene | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin E; Assigned to Arm(s): Vitamin E | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin C; Assigned to Arm(s): Vitamin C | Intervention Type: DIETARY_SUPPLEMENT; Name: Multivitamin; Assigned to Arm(s): Multivitamin | Intervention Type: DIETARY_SUPPLEMENT; Name: Beta-carotene; Assigned to Arm(s): Beta-carotene
B: Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin C; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin E; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: beta-carotene; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: folic acid/Vitamin B6/Vitamin B12; Assigned to Arm(s): N/A
C: Arm Label: Lutein/Zeaxanthin; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Lutein/zeaxanthin | Arm Label: DHA/EPA; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: DHA/EPA | Arm Label: Lutein/Zeaxanthin + DHA/EPA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lutein/zeaxanthin and DHA/EPA | Arm Label: Placebo/Control; Type: PLACEBO_COMPARATOR; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Lutein/zeaxanthin; Assigned to Arm(s): Lutein/Zeaxanthin | Intervention Type: DIETARY_SUPPLEMENT; Name: DHA/EPA; Assigned to Arm(s): DHA/EPA | Intervention Type: DRUG; Name: Lutein/zeaxanthin and DHA/EPA; Assigned to Arm(s): Lutein/Zeaxanthin + DHA/EPA
D: Arm Label: Active VITATOPS Tablet (folic acid 2mg, B6 25mg , B12 500ug); Type: ACTIVE_COMPARATOR; Interventions: Drug: Active VITATOPS Tablet (folic acid 2mg, B6 25mg , B12 500ug) or placebo | Arm Label: Placebo Tablet; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Active VITATOPS Tablet (folic acid 2mg, B6 25mg , B12 500ug) or placebo; Assigned to Arm(s): Active VITATOPS Tablet (folic acid 2mg, B6 25mg , B12 500ug) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo Tablet

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Physicians' Health Study II: Trial of Vitamins in the Chemoprevention of Cancer, CVD, and Eye Disease
Brief Summary: The use of vitamin E, vitamin C, beta carotene, and/or multivitamins may keep cancer, cardiovascular disease, eye diseases, or cognitive decline from occurring. This randomized clinical trial studied vitamin E, vitamin C, beta carotene, and/or multivitamins to see how well they work compared with placebos in preventing cancer, cardiovascular disease, eye disease, and cognitive decline in male doctors aged 50 years and older.


Options:
A: Arm Label: Lutein/Zeaxanthin; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Lutein/zeaxanthin | Arm Label: DHA/EPA; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: DHA/EPA | Arm Label: Lutein/Zeaxanthin + DHA/EPA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lutein/zeaxanthin and DHA/EPA | Arm Label: Placebo/Control; Type: PLACEBO_COMPARATOR; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Lutein/zeaxanthin; Assigned to Arm(s): Lutein/Zeaxanthin | Intervention Type: DIETARY_SUPPLEMENT; Name: DHA/EPA; Assigned to Arm(s): DHA/EPA | Intervention Type: DRUG; Name: Lutein/zeaxanthin and DHA/EPA; Assigned to Arm(s): Lutein/Zeaxanthin + DHA/EPA
B: Arm Label: Saffron; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Saffron | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Saffron; Assigned to Arm(s): Saffron | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Vitamin E; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin E | Arm Label: Vitamin C; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin C | Arm Label: Multivitamin; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Multivitamin | Arm Label: Beta-carotene; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Beta-carotene | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin E; Assigned to Arm(s): Vitamin E | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin C; Assigned to Arm(s): Vitamin C | Intervention Type: DIETARY_SUPPLEMENT; Name: Multivitamin; Assigned to Arm(s): Multivitamin | Intervention Type: DIETARY_SUPPLEMENT; Name: Beta-carotene; Assigned to Arm(s): Beta-carotene
D: Arm Label: OT-551 antioxidant eye drop; Type: EXPERIMENTAL; Interventions: Drug: OT-551 antioxidant eye drop | Intervention Type: DRUG; Name: OT-551 antioxidant eye drop; Assigned to Arm(s): OT-551 antioxidant eye drop

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Double Guide Wire Placement Compared With Conventional Method in Cases of Difficult Common Bile Duct Cannulation in Endoscopic Retrograde Cholangiopancreatography Procedures. A Controlled Multicentred Randomized Trial.
Brief Summary: The purpose of this study is to determine if the double guide wire technique is more effective than the conventional method in those cases of difficult selective biliary cannulation in the ERCP procedures.


Options:
A: Arm Label: A (NS+Placebo); Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal Saline, Drug: Placebo | Arm Label: B (NS+IND); Type: ACTIVE_COMPARATOR; Interventions: Drug: Indomethacin, Drug: Normal Saline | Arm Label: C (LR+Placebo); Type: ACTIVE_COMPARATOR; Interventions: Drug: Lactated Ringer's Solution, Drug: Placebo | Arm Label: D (LR+IND); Type: EXPERIMENTAL; Interventions: Drug: Indomethacin, Drug: Lactated Ringer's Solution | Intervention Type: DRUG; Name: Indomethacin; Assigned to Arm(s): B (NS+IND), D (LR+IND) | Intervention Type: DRUG; Name: Lactated Ringer's Solution; Assigned to Arm(s): C (LR+Placebo), D (LR+IND) | Intervention Type: DRUG; Name: Normal Saline; Assigned to Arm(s): A (NS+Placebo), B (NS+IND) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): A (NS+Placebo), C (LR+Placebo)
B: Intervention Type: PROCEDURE; Name: Double guide wire technique; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Standard bile duct cannulation; Assigned to Arm(s): N/A
C: Arm Label: 0.035 guidewire; Type: ACTIVE_COMPARATOR; Interventions: Device: Conventional 0.035 guidewire | Arm Label: Olympus Visiglide 0.025 guidewire; Type: ACTIVE_COMPARATOR; Interventions: Device: Olympus Visiglide 0.025 guidewire | Intervention Type: DEVICE; Name: Conventional 0.035 guidewire; Assigned to Arm(s): 0.035 guidewire | Intervention Type: DEVICE; Name: Olympus Visiglide 0.025 guidewire; Assigned to Arm(s): Olympus Visiglide 0.025 guidewire
D: Arm Label: loop-tip arm; Type: EXPERIMENTAL; Interventions: Device: Loop-tip wire (Cook Medical) for the cannulation of the CBD | Arm Label: Control arm; Type: ACTIVE_COMPARATOR; Interventions: Device: Cannulotome CT-25mm Cook Medical | Intervention Type: DEVICE; Name: Loop-tip wire (Cook Medical) for the cannulation of the CBD; Assigned to Arm(s): loop-tip arm | Intervention Type: DEVICE; Name: Cannulotome CT-25mm Cook Medical; Assigned to Arm(s): Control arm

Answer: B